Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

(2009) Andrew Hill et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

(2009) Jose R Arribas et al.   AIDS

Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis

(2009) Jean‐Jacques Parienti et al.   CLINICAL INFECTIOUS DISEASES

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy

(2008) James H Willig et al.   AIDS

Double-Boosted Protease Inhibitor Antiretroviral Regimens

(2008) Esteban Ribera et al.   DRUGS

Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir

(2008) Sandra M J De Meyer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES